| Ocupress (U.S.N.L.M.) | |
|---|---|
| Dosing | 1 drop bid |
| Chem Specs | carteolol HCL 1% |
| Quantities | 5, 10, 15ml |
| Cost | 21.00/5ml |
| Class | Nonselective beta blocker, intrinsic sympathomimetic activity. |
| Action | Reduces aqueous humor production. |
| Usage | Indicated for lowering IOP with chronic open-angle glaucoma or ocular hypertension. |
| May be used concomitantly with pilocarpine and other miotics, and/or epinephrine or dipivefrin, and/or systemically administered carbonic anhydrase inhibitors. May be used concomitantly with pilocarpine and other miotics, and/or epinephrine or dipivefrin, and/or systemically administered carbonic anhydrase inhibitors. |
|
| Contraindications | Bronchial asthma, severe COPD, sinus bradycardia; second and third-degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component. Bronchial asthma, severe COPD, sinus bradycardia; second and third-degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component. |
| Pediatric use | Safety and effectiveness in pediatric patients have not been established. |
| Pregnancy | Category C. Teratogenic in rats but not mice at 200 times the maximum human dose. |
| Carteolol may affect heart rate and cholesterol less than other beta-blockers. Does not cross blood brain-barrier so may avoid depression side effect. BAK preserved. Carteolol may affect heart rate and cholesterol less than other beta-blockers. Does not cross blood brain-barrier so may avoid depression side effect. BAK preserved. |